Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Yonsei University

Status: Completed

Conditions: Antineoplastic Agents; Breast Neoplasms; Survival Analysis; Therapeutic Uses

Treatments: Drug: tamoxifen

Study type: Observational

Funder types: Other

Identifiers

NCT01169792

4-2009-0483

Details and patient eligibility

About

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.

The investigators want to

• evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
• analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age ≥ 18 years
• Breast cancer patients who underwent surgery

Exclusion criteria

• None

Trial design

0 participants in 1 patient group

Breast cancer patients

Description:

Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.

Treatment:

Drug: tamoxifen